Apogee Therapeutics Inc (APGE) Stock Price, Quote & News

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

BillionerOfKing Feb. 22 at 4:15 PM

$APGE Current Stock Price: $68.42 Contracts to trade: $70.0 APGE Mar 20 2026 Call Entry: $4.50 Exit: $6.86 ROI: 52% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

AliciaNester280 Feb. 18 at 1:16 PM

$APGE Obesity-focused biotech with strong thematic tailwinds.

0 · Reply

SuperGreenToday Feb. 12 at 8:48 PM

$APGE Share Price: $69.93 Contract Selected: Jul 17, 2026 $70 Calls Buy Zone: $11.05 – $13.65 Target Zone: $20.58 – $25.15 Potential Upside: 76% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Feb. 10 at 5:39 PM

BTIG⬆️1H26 Top Pick $NKTR's PT to $151 and reiterated at Buy $CRVS $REGN - SNY $LLY KYMR $APGE Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2021276476335636938?s=20

0 · Reply

Quantumup Feb. 10 at 5:21 PM

William Blair⬆️ $NKTR to Outperform and provided its Take and Stock Thoughts. $CRVS $REGN - SNY $APGE $KYMR William Blair said: Rezpeg, continues to demonstrate deepening of response and durability with longer-term data—Re: durability, WB noted, there appears to be no meaningful deterioration of response when comparing the monthly dosing to the quarterly dosing—noted, there were no reported cases of conjunctivitis, erythema, oral ulcers, cardiovascular adverse events, or malignancies in the Phase 2 REZOLVE-AD study of rezpeg. Here's what else William Blair had to say: https://x.com/Quantumup1/status/2021272497862115591?s=20

0 · Reply

SuperGreenToday Feb. 2 at 8:38 PM

$APGE Share Price: $65.73 Contract Selected: Jul 17, 2026 $70 Calls Buy Zone: $9.35 – $11.55 Target Zone: $16.56 – $20.23 Potential Upside: 67% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 30 at 7:40 PM

$APGE Share Price: $66.59 Contract Selected: Jul 17, 2026 $70 Calls Buy Zone: $9.35 – $11.55 Target Zone: $17.27 – $21.10 Potential Upside: 74% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Fizz26 Jan. 30 at 5:05 PM

$DJIA $APGE garbage

0 · Reply

Fizz26 Jan. 30 at 4:23 PM

$DJIA $APGE getting dumped! I’m out

0 · Reply

Leondog1992 Jan. 30 at 3:23 PM

$APGE $IRTC $MDB $HL $IESC

0 · Reply

Apogee Therapeutics to Participate in Upcoming March Conferences

Feb 5, 2026, 8:00 AM EST - 19 days ago

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 21, 2026, 10:29 AM EST - 4 weeks ago

Apogee Therapeutics: 2026 Inflection Point In Immunology

Jan 6, 2026, 2:28 PM EST - 7 weeks ago

Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript

Jan 6, 2026, 6:00 AM EST - 7 weeks ago

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Jan 5, 2026, 4:01 PM EST - 7 weeks ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Dec 3, 2025, 12:23 PM EST - 2 months ago

Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 7:10 AM EST - 3 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 7:00 AM EST - 3 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Nov 3, 2025, 7:30 AM EST - 4 months ago

Apogee Therapeutics to Participate in Upcoming Conferences

Oct 10, 2025, 4:01 PM EDT - 4 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Oct 9, 2025, 8:29 AM EDT - 4 months ago

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

HELE RACE

Oct 8, 2025, 9:52 PM EDT - 4 months ago

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Oct 8, 2025, 4:01 PM EDT - 4 months ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Sep 11, 2025, 7:30 AM EDT - 5 months ago

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Sep 3, 2025, 7:30 AM EDT - 6 months ago

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Jul 8, 2025, 4:50 PM EDT - 8 months ago

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Jul 7, 2025, 6:00 AM EDT - 8 months ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Jul 6, 2025, 6:00 PM EDT - 8 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

May 29, 2025, 7:30 AM EDT - 9 months ago

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 12, 2025, 4:04 PM EDT - 10 months ago

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class

May 12, 2025, 6:05 AM EDT - 10 months ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

May 12, 2025, 6:00 AM EDT - 10 months ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

May 1, 2025, 8:00 AM EDT - 10 months ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Apr 14, 2025, 8:04 AM EDT - 11 months ago

Apogee Therapeutics: Engineering Biologic Dominance

Mar 3, 2025, 12:16 PM EST - 1 year ago

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Mar 3, 2025, 6:05 AM EST - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Mar 3, 2025, 6:00 AM EST - 1 year ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Feb 28, 2025, 4:00 PM EST - 1 year ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Feb 25, 2025, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 7:00 AM EST - 1 year ago

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Jan 29, 2025, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Dec 2, 2024, 6:00 AM EST - 1 year ago

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Nov 29, 2024, 1:00 PM EST - 1 year ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Nov 18, 2024, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Nov 10, 2024, 9:55 AM EST - 1 year ago

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 4, 2024, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Sep 12, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Aug 12, 2024, 6:30 AM EDT - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Jun 18, 2024, 10:05 AM EDT - 1 year ago

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

May 28, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

May 23, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

May 13, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

Mar 25, 2024, 7:00 AM EDT - 2 years ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

BillionerOfKing Feb. 22 at 4:15 PM

0 · Reply

AliciaNester280 Feb. 18 at 1:16 PM

$APGE Obesity-focused biotech with strong thematic tailwinds.

0 · Reply

SuperGreenToday Feb. 12 at 8:48 PM

0 · Reply

Quantumup Feb. 10 at 5:39 PM

0 · Reply

Quantumup Feb. 10 at 5:21 PM

0 · Reply

SuperGreenToday Feb. 2 at 8:38 PM

0 · Reply

SuperGreenToday Jan. 30 at 7:40 PM

0 · Reply

Fizz26 Jan. 30 at 5:05 PM

$DJIA $APGE garbage

0 · Reply

Fizz26 Jan. 30 at 4:23 PM

$DJIA $APGE getting dumped! I’m out

0 · Reply

Leondog1992 Jan. 30 at 3:23 PM

$APGE $IRTC $MDB $HL $IESC

0 · Reply

Fizz26 Jan. 29 at 3:21 PM

$DJIA $APGE reason why there was a big sell off

0 · Reply

Fizz26 Jan. 29 at 3:00 PM

$DJIA $APGE scam

0 · Reply

SuperGreenToday Jan. 24 at 4:42 PM

$APGE Share Price: $70.03 Contract Selected: Jul 17, 2026 $75 Calls Buy Zone: $11.05 – $13.65 Target Zone: $18.25 – $22.31 Potential Upside: 56% ROI Time to Expiration: 173 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

notreload_ai Jan. 24 at 4:34 PM

$APGE stock drops 12% after major investor Fairmount Funds Management sells 1.75 million shares worth $133.5 million, significantly reducing its position. https://notreload.xyz/fairmount-funds-sells-stake-in-apogee-therapeutics/

0 · Reply

WAJeff Jan. 24 at 12:56 AM

Today was easily the most boring trading day of the year. I took some $MRNA profit (yesterday a near term top), cut $APGE at a small loss, added a smidge more $VOYG and just felt bored out of my mind for the most part. This was like watching Downton Abbey or a documentary on scarves.

0 · Reply

JFais Jan. 23 at 8:39 PM

Better stated: $APGE- we've seen a good number of + biotech binaries lately, perhaps due for a significant (downward) revaluation here? 4x avg volume so far on the high side, but certainly far from panic levels (as of yet) Also, atopic dermatitis very crowded & while the pie is very large, it's limited as well (yes, it can be both) New drugs shining like $CRVS ITK will be at the expense of other potential entrants like $APGE or $KYMR IMO

0 · Reply

JFais Jan. 23 at 8:36 PM

$APGE- we've seen a good number of + biotech binaries lately, perhaps due for a significant (downward) revaluation? 4x avg volume so far on the high side, but certainly far from panic levels (as of yet)

0 · Reply